[{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Variational AI","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"ATR","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Variational AI","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Variational AI"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PARP-1","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Andira Pharmaceuticals","sponsor":"University of British Columbia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Andira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andira Pharmaceuticals \/ University of British Columbia","highestDevelopmentStatusID":"4","companyTruncated":"Andira Pharmaceuticals \/ University of British Columbia"},{"orgOrder":0,"company":"Precision NanoSystems","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"RBI-1000","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Precision NanoSystems","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision NanoSystems \/ Replicate Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"Precision NanoSystems \/ Replicate Bioscience"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Sudocetaxel Zendusortide","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"K1.1 mRNA","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TLD-1433","moa":"ROS receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Private Placement","leadProduct":"TLD-1433","moa":"ROS receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Theralase Technologies \/ TSX Venture Exchange","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ TSX Venture Exchange"},{"orgOrder":0,"company":"Theralase Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rutherrin","moa":"Transferrin-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theralase Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theralase Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theralase Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Onco-Innovations","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PNKP","graph1":"Oncology","graph2":"Preclinical","graph3":"Onco-Innovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Onco-Innovations \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Onco-Innovations \/ Inapplicable"},{"orgOrder":0,"company":"M4K Pharma","sponsor":"Conscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"ALK-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"M4K Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M4K Pharma \/ Conscience","highestDevelopmentStatusID":"4","companyTruncated":"M4K Pharma \/ Conscience"},{"orgOrder":0,"company":"Jay Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Jay Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Jay Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jay Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Notch Therapeutics","sponsor":"Allogene Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Notch Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Notch Therapeutics \/ Allogene Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Notch Therapeutics \/ Allogene Therapeutics"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"Natural Sciences and Engineering Council","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"QBSAU","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qu Biologics Inc \/ Natural Sciences and Engineering Council","highestDevelopmentStatusID":"4","companyTruncated":"Qu Biologics Inc \/ Natural Sciences and Engineering Council"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Harvard Medical School","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BriaCell Therapeutics \/ Harvard Medical School","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ Harvard Medical School"},{"orgOrder":0,"company":"Radiant Biotherapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"4-1BB","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiant Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Radiant Biotherapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Pharma Inventor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rakovina Therapeutics \/ Pharma Inventor","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Pharma Inventor"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Variational AI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rakovina Therapeutics \/ Variational AI","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Variational AI"},{"orgOrder":0,"company":"Reverb Therapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Reverb Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reverb Therapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Reverb Therapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ExCellThera \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"ExCellThera \/ Astellas Pharma"},{"orgOrder":0,"company":"Phenomic AI","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Phenomic AI","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Phenomic AI \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Phenomic AI \/ Astellas Pharma"},{"orgOrder":0,"company":"Radiant Biotherapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Radiant Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Radiant Biotherapeutics \/ Amplitude Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Radiant Biotherapeutics \/ Amplitude Ventures"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"kt-4000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"NRC IRAP","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"DDR","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rakovina Therapeutics \/ NRC IRAP","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ NRC IRAP"},{"orgOrder":0,"company":"Reverb Therapeutics","sponsor":"Royalmount Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Reverb Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reverb Therapeutics \/ Royalmount Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Reverb Therapeutics \/ Royalmount Laboratories"},{"orgOrder":0,"company":"Symvivo","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Symvivo","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Symvivo \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Symvivo \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zymeworks \/ Daiichi Sankyo","highestDevelopmentStatusID":"4","companyTruncated":"Zymeworks \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zymeworks \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Zymeworks \/ Merck & Co"},{"orgOrder":0,"company":"Repare Therapeutics","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Debio 0123","moa":"||WEE1","graph1":"Oncology","graph2":"Preclinical","graph3":"Repare Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Repare Therapeutics \/ Debiopharm","highestDevelopmentStatusID":"4","companyTruncated":"Repare Therapeutics \/ Debiopharm"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Bria-OTS","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaCell Therapeutics \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Onco-Innovations","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"PNKP","graph1":"Oncology","graph2":"Preclinical","graph3":"Onco-Innovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onco-Innovations \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Onco-Innovations \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"TSX Venture Exchange","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ TSX Venture Exchange","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ TSX Venture Exchange"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Variational AI","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"ATR","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Variational AI","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Variational AI"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"K1.1","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"TH1904","moa":"Sortilin-1 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Sunshine Biopharma","sponsor":"Jewish General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Adva-27a","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Preclinical","graph3":"Sunshine Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sunshine Biopharma \/ Jewish General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Sunshine Biopharma \/ Jewish General Hospital"},{"orgOrder":0,"company":"Starpax Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"SN38","moa":"||Topoisomerase I","graph1":"Oncology","graph2":"Preclinical","graph3":"Starpax Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Starpax Biopharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Starpax Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"NMDA subunit-2B receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Algernon Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Algernon Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2023","type":"Private Placement","leadProduct":"ZW171","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zymeworks \/ EcoR1 Capital","highestDevelopmentStatusID":"4","companyTruncated":"Zymeworks \/ EcoR1 Capital"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"University of Wisconsin","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Bria-Pros","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ University of Wisconsin","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ University of Wisconsin"},{"orgOrder":0,"company":"Essa Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EPI-8207","moa":"ANITAC","graph1":"Oncology","graph2":"Preclinical","graph3":"Essa Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Essa Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Essa Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"kt-3283","moa":"PARP-HDAC","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rakovina Therapeutics","sponsor":"St. Baldrick\u2019s Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Kt-3000","moa":"PARP","graph1":"Oncology","graph2":"Preclinical","graph3":"Rakovina Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rakovina Therapeutics \/ St. Baldrick\u2019s Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Rakovina Therapeutics \/ St. Baldrick\u2019s Foundation"},{"orgOrder":0,"company":"ProteinQure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ProteinQure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"ProteinQure \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ProteinQure \/ Inapplicable"},{"orgOrder":0,"company":"KisoJi Biotechnology","sponsor":"Cancer Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"KJ-103","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"KisoJi Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KisoJi Biotechnology \/ Cancer Research","highestDevelopmentStatusID":"4","companyTruncated":"KisoJi Biotechnology \/ Cancer Research"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Procare Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BVX-0918C","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ Procare Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Biovaxys \/ Procare Pharmaceutical"},{"orgOrder":0,"company":"Revive Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bucillamine","moa":"Glutathione","graph1":"Oncology","graph2":"Preclinical","graph3":"Revive Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Revive Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Revive Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"B7-H3","graph1":"Oncology","graph2":"Preclinical","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"McGill University","sponsor":"Brain Cancer Canada","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University \/ Brain Cancer Canada","highestDevelopmentStatusID":"4","companyTruncated":"McGill University \/ Brain Cancer Canada"},{"orgOrder":0,"company":"Onco-Innovations","sponsor":"University of Alberta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"PNKP","graph1":"Oncology","graph2":"Preclinical","graph3":"Onco-Innovations","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Onco-Innovations \/ University of Alberta","highestDevelopmentStatusID":"4","companyTruncated":"Onco-Innovations \/ University of Alberta"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The agreement aims to expand the research scope of its second-generation nanoparticle formulation of its Polynucleotide Kinase 3'-Phosphatase Inhibitor technology to encompass hard-to-treat cancers.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 13, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : University of Alberta

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The funding will be used to advance a gene therapy treatment for pediatric high-grade gliomas (pHGG), an aggressive and often fatal group of brain cancers.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 12, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Brain Cancer Canada

                          Deal Size : $0.1 million

                          Deal Type : Funding

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Bucillamine is an investigational small molecule, works as a glutathione restorator. It is being studied as a potential treatment for solid tumors.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 10, 2025

                          Lead Product(s) : Bucillamine

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : BriaPro is developing novel, high affinity antibodies to B7-H3, a promising anti-cancer target for drugs both effecting cancer cells and blocking immune checkpoint activity.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          April 10, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Company is developing an ATR inhibitor, small molecule drug candidate, which is currently being evaluated for treating central nervous system malignancies.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 12, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Variational AI

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The funding will be used for the pre-clinical development of an ALK2 inhibitor for the treatment of diffuse intrinsic pontine glioma.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 27, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Conscience

                          Deal Size : $1.1 million

                          Deal Type : Funding

                          blank

                          07

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The outcome of the study validated the potential of the PNKP Compound as a potent, single-agent therapy in combating colorectal cancer, specifically in cases where tumours exhibit PTEN deficiencies.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 14, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The collaboration aims to develop AI-designed ATR inhibitors for cancers, advancing shortlisted molecules to synthesis & preclinical validation, accelerating oncology drug discovery.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 13, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Variational AI

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Onco-Innovations Limited announces exclusive licensing of PNKP inhibitors to enhance cancer treatment by targeting DNA repair mechanisms, aiming to improve radiation therapy effectiveness.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 09, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Rakovina is developing PARP1-selective inhibitors, small molecule drugs, capable of crossing the blood-brain barrier. They are being evalutaed for treating BRCA-mutated breast cancer and glioblastoma.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 06, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank